Yıl 2016,
, 43 - 49, 01.08.2016
Öz
The goal of HCV treatment is to prevent cirrhosis, hepatocellularcarcinoma, liver-related deaths. The development of direct-actingantiviral (DAA) agents which target various steps in HCV lifecycleled to a revolution by providing nearly complete eradication ofHCV. The new treatment regimens with high cure rates havechanged the standards of care in the regions where patients haveaccess to new treatments. This review addresses the recent updatesin management of chronic hepatitis C infection.Keywords: Hepatitis C, New treatments, Direct antiviral agents
Anahtar Kelimeler
Kaynakça
- Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon
- alfa-2b plus ribavirin compared with interferon alfa-2b
- plus ribavirin for initial treatment of chronic hepatitis C: a
- randomised trial. Lancet 2001;358:958-65.
- Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon
- alfa-2a plus ribavirin for chronic hepatitis C virus infection.
- N Engl J Med 2002;47:975-82.
- Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferonalpha2a
- and ribavirin combination therapy in chronic hepatitis
- C: a randomized study of treatment duration and ribavirin
- dose. Ann Intern Med 2004;140:346-55.
- Bacon BR, Gordon SC, Lawitz E, et al.
- Boceprevir for previously treated chronic HCV genotype 1
- infection. N Engl J
- Med 2011;364:1207–17.
- Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir
- for previously untreated chronic hepatitis C virus infection. N
- Engl J Med 2011;364:2405-16.
- Poordad F, McCone Jr J, Bacon BR, et al. Boceprevir for
- untreated chronic HCV genotype 1 infection. N Engl J Med
- 364:1195-206.
- Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment
- of HCV infection. N Engl J Med 2011;364:2417-28.
- EASL Recommendations on Treatment of Hepatitis C 2015.
- J Hepatol 2015;63:199-236.
- AASLD/IDSA/IAS-USA. Recommendations for testing
- managing, and treating hepatitis C. [Accessed on October
- .Available from: URL: http://www.hcvguidelines.org
- Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C
- virus genotypes 4, 5, and 6: an international consensus report.
- Liver Int 2010;30:342-55.
- Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir
- plus sofosbuvir, with or without ribavirin, to treat chronic
- infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive
- patients: the COSMOS randomised study. Lancet 2014
- 1756-65.
- Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously
- untreated chronic hepatitis C 79. infection. N Engl J Med
- 368:1878-87.
- Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir
- for hepatitis C genotype 2 or 3 in patients without treatment
- options. N Engl J Med 2013; 368:1867-77.
- Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and
- sofosbuvir for previously treated HCV genotype 1 infection.
- N Engl J Med 2014;370:1483-93.
- Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir
- for untreated HCV genotype 1 infection. N Engl J Med 2014
- 1889-98.
- Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir
- and sofosbuvir for 8 or 12 weeks for chronic HCV without
- cirrhosis. N Engl J Med 2014;370:1879-88.
- Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al.
- Daclatasvir plus sofosbuvir for previously treated or untreated
- chronic HCV infection. N Engl J Med 2014;370:211–21.
- Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus
- Sofosbuvir for HCV in patients coinected with HIV-1. N Eng
- J Med 2015;373:714-25.
- Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR
- Crawford D. Treatment of HCV with ABT-450/rombitasvir
- and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-
- Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV
- with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N
- Engl J Med 2014;370:1604-14.
- Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci
- P, Maieron A. ABT-450, ritonavir, ombitasvir, and dasabuvir
- achieves 97% and 100% sustained virologic response with or
- without ribavirin in treatmentexperienced patients with HCV
- genotype 1b infection. Gastroenterology 2014; 147:359-365.
- e1.
- Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper
- C. ABT-450/r-ombitasvir and dasabuvir with or without
- ribavirin for HCV. N Engl J Med 2014; 370:1983-92.
- Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir
- and dasabuvir with ribavirin for hepatitis C with cirrhosis. N
- Engl J Med 2014;370:1973-82.
- Kwo P, Gitlin N, Nahass R, et al. A phase 3, randomised
- open-label study to evaluate the efficacy and safety of 8 and
- weeks of simeprevir (SMV) plus sofosbuvir (SOF) in
- treatment-naive and –experienced patients with chronic HCV
- genotype 1 infection without cirrhosis: Optimist-1. J Hepatol
- 62 (Suppl 2): S270.
- Lawitz E, Matusow G, DeJesus E, et al. A phase 3, open
- label, single-arm study to evaluate the efficacy and safety
- of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in
- treatment-naive or –experienced patients with chronic HCV
- genotype 1 infection and cirrhosis: Optimist-2. J Hepatol
- 62 (Suppl 2): S264-265.
- Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis
- The outcome of antiviral therapy in HCV genotype 2 and
- genotype 3 infected patients with chronic hepatitis. Aliment
- Pharmacol Ther 2008; 28: 397-404.
- Nelson DR, Cooper JN, Lalezari JP, et al, for the ALLY-3
- Study Team. All-oral 12-week treatment with daclatasvir
- plus sofosbuvir in patients with hepatitis C virus genotype
- infection: ALLY-3 phase III study. Hepatology
- 61:1127-35.
- Hezode C, De Ledinghen V, Fonatine H, et al. Daclatasvir
- plus sofosbuvir with or without ribavirin in patients with
- HCV genotype 3 infection: Interim analysis of a French
- multicenter compassionate program. J Hepatol 2015; 62
- (Suppl 2): S265-266.
- Mohamoud YA, Mumtaz GR, Riome S, et al. The
- epidemiology of hepatitis C virus in Egypt: a systematic
- review and data synthesis. BMC Infect Dis 2013;13:1-21.
Yıl 2016,
, 43 - 49, 01.08.2016
Öz
The goal of HCV treatment is to prevent cirrhosis, hepatocellularcarcinoma, liver-related deaths. The development of direct-actingantiviral (DAA) agents which target various steps in HCV lifecycleled to a revolution by providing nearly complete eradication ofHCV. The new treatment regimens with high cure rates havechanged the standards of care in the regions where patients haveaccess to new treatments. This review addresses the recent updatesin management of chronic hepatitis C infection.Keywords: Hepatitis C, New treatments, Direct antiviral agents
Kaynakça
- Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon
- alfa-2b plus ribavirin compared with interferon alfa-2b
- plus ribavirin for initial treatment of chronic hepatitis C: a
- randomised trial. Lancet 2001;358:958-65.
- Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon
- alfa-2a plus ribavirin for chronic hepatitis C virus infection.
- N Engl J Med 2002;47:975-82.
- Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferonalpha2a
- and ribavirin combination therapy in chronic hepatitis
- C: a randomized study of treatment duration and ribavirin
- dose. Ann Intern Med 2004;140:346-55.
- Bacon BR, Gordon SC, Lawitz E, et al.
- Boceprevir for previously treated chronic HCV genotype 1
- infection. N Engl J
- Med 2011;364:1207–17.
- Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir
- for previously untreated chronic hepatitis C virus infection. N
- Engl J Med 2011;364:2405-16.
- Poordad F, McCone Jr J, Bacon BR, et al. Boceprevir for
- untreated chronic HCV genotype 1 infection. N Engl J Med
- 364:1195-206.
- Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment
- of HCV infection. N Engl J Med 2011;364:2417-28.
- EASL Recommendations on Treatment of Hepatitis C 2015.
- J Hepatol 2015;63:199-236.
- AASLD/IDSA/IAS-USA. Recommendations for testing
- managing, and treating hepatitis C. [Accessed on October
- .Available from: URL: http://www.hcvguidelines.org
- Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C
- virus genotypes 4, 5, and 6: an international consensus report.
- Liver Int 2010;30:342-55.
- Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir
- plus sofosbuvir, with or without ribavirin, to treat chronic
- infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive
- patients: the COSMOS randomised study. Lancet 2014
- 1756-65.
- Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously
- untreated chronic hepatitis C 79. infection. N Engl J Med
- 368:1878-87.
- Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir
- for hepatitis C genotype 2 or 3 in patients without treatment
- options. N Engl J Med 2013; 368:1867-77.
- Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and
- sofosbuvir for previously treated HCV genotype 1 infection.
- N Engl J Med 2014;370:1483-93.
- Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir
- for untreated HCV genotype 1 infection. N Engl J Med 2014
- 1889-98.
- Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir
- and sofosbuvir for 8 or 12 weeks for chronic HCV without
- cirrhosis. N Engl J Med 2014;370:1879-88.
- Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al.
- Daclatasvir plus sofosbuvir for previously treated or untreated
- chronic HCV infection. N Engl J Med 2014;370:211–21.
- Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus
- Sofosbuvir for HCV in patients coinected with HIV-1. N Eng
- J Med 2015;373:714-25.
- Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR
- Crawford D. Treatment of HCV with ABT-450/rombitasvir
- and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-
- Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV
- with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N
- Engl J Med 2014;370:1604-14.
- Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci
- P, Maieron A. ABT-450, ritonavir, ombitasvir, and dasabuvir
- achieves 97% and 100% sustained virologic response with or
- without ribavirin in treatmentexperienced patients with HCV
- genotype 1b infection. Gastroenterology 2014; 147:359-365.
- e1.
- Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper
- C. ABT-450/r-ombitasvir and dasabuvir with or without
- ribavirin for HCV. N Engl J Med 2014; 370:1983-92.
- Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir
- and dasabuvir with ribavirin for hepatitis C with cirrhosis. N
- Engl J Med 2014;370:1973-82.
- Kwo P, Gitlin N, Nahass R, et al. A phase 3, randomised
- open-label study to evaluate the efficacy and safety of 8 and
- weeks of simeprevir (SMV) plus sofosbuvir (SOF) in
- treatment-naive and –experienced patients with chronic HCV
- genotype 1 infection without cirrhosis: Optimist-1. J Hepatol
- 62 (Suppl 2): S270.
- Lawitz E, Matusow G, DeJesus E, et al. A phase 3, open
- label, single-arm study to evaluate the efficacy and safety
- of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in
- treatment-naive or –experienced patients with chronic HCV
- genotype 1 infection and cirrhosis: Optimist-2. J Hepatol
- 62 (Suppl 2): S264-265.
- Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis
- The outcome of antiviral therapy in HCV genotype 2 and
- genotype 3 infected patients with chronic hepatitis. Aliment
- Pharmacol Ther 2008; 28: 397-404.
- Nelson DR, Cooper JN, Lalezari JP, et al, for the ALLY-3
- Study Team. All-oral 12-week treatment with daclatasvir
- plus sofosbuvir in patients with hepatitis C virus genotype
- infection: ALLY-3 phase III study. Hepatology
- 61:1127-35.
- Hezode C, De Ledinghen V, Fonatine H, et al. Daclatasvir
- plus sofosbuvir with or without ribavirin in patients with
- HCV genotype 3 infection: Interim analysis of a French
- multicenter compassionate program. J Hepatol 2015; 62
- (Suppl 2): S265-266.
- Mohamoud YA, Mumtaz GR, Riome S, et al. The
- epidemiology of hepatitis C virus in Egypt: a systematic
- review and data synthesis. BMC Infect Dis 2013;13:1-21.
Toplam 104 adet kaynakça vardır.
Ayrıntılar
| Konular | Klinik Tıp Bilimleri |
|---|---|
| Diğer ID | JA87AU84BP |
| Bölüm | Reviews |
| Yazarlar | |
| Yayımlanma Tarihi | 1 Ağustos 2016 |
| Yayımlandığı Sayı | Yıl 2016 |